Stockscreener 앱 받기
35.49
1.70%
0.59
전일 마감가:
$34.90
열려 있는:
$35.36
하루 거래량:
193.03K
Relative Volume:
0.15
시가총액:
$4.15B
수익:
$22.57M
순이익/손실:
$-212.73M
주가수익비율:
-19.67
EPS:
-1.8045
순현금흐름:
$-142.19M
1주 성능:
+4.74%
1개월 성능:
+12.61%
6개월 성능:
+0.13%
1년 성능:
+82.40%
1일 변동 폭
$34.27
$36.16
1주일 범위
$33.81
$36.34
52주 변동 폭
$19.28
$42.20
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
명칭
Newamsterdam Pharma Company Nv
전화
35 206 2971
주소
GOOIMEER 2-35, NARRDEN
Compare NAMS vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
35.49 | 4.07B | 22.57M | -212.73M | -142.19M | -1.8045 |
VRTX
Vertex Pharmaceuticals Inc
|
520.10 | 134.02B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
669.53 | 68.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
924.65 | 58.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
319.22 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.25 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-18 | 개시 | Truist | Buy |
| 2025-10-20 | 재개 | H.C. Wainwright | Buy |
| 2025-08-25 | 개시 | Wells Fargo | Overweight |
| 2025-07-17 | 개시 | Goldman | Neutral |
| 2025-06-17 | 개시 | Citigroup | Buy |
| 2025-06-10 | 개시 | Stifel | Buy |
| 2025-06-04 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-30 | 개시 | H.C. Wainwright | Buy |
| 2024-05-15 | 개시 | TD Cowen | Buy |
| 2024-03-14 | 개시 | Scotiabank | Sector Outperform |
| 2024-01-18 | 개시 | Guggenheim | Buy |
| 2024-01-16 | 개시 | Piper Sandler | Overweight |
| 2023-10-30 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Newamsterdam Pharma Company Nv 주식(NAMS)의 최신 뉴스
NewAmsterdam Pharma puts obicetrapib in Alzheimer’s spotlight at AAIC 2026 - Stock Titan
NewAmsterdam Pharma Company N.V. - TradingView
Price to sales forward of NewAmsterdam Pharma Company N.V. – BOATS:NAMSW - TradingView
Enterprise value to revenue forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMSW - TradingView
Enterprise value to EBIT forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMSW - TradingView
Price to book forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMSW - TradingView
Understanding the Setup: (NAMS) and Scalable Risk - Stock Traders Daily
Price to book forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMS - TradingView
Price to book forward of NewAmsterdam Pharma Company N.V. – LSX:A3DUAC - TradingView
NewAmsterdam Pharma Company N.V. Actuals & Estimates (NASDAQ:NAMS) - TradingView
NAMS Forecast — Price Target — Prediction for 2027 - TradingView
NewAmsterdam Pharma Company N.V. Actuals & Estimates (MUN:KH6) - TradingView
Enterprise value to EBITDA forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMS - TradingView
Enterprise value to revenue forward of NewAmsterdam Pharma Company N.V. – LSX:A3DUAC - TradingView
NewAmsterdam Pharma Company N.V. Actuals & Estimates (LSX:A3DUAC) - TradingView
Enterprise value to EBIT forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMS - TradingView
Price to earnings forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMS - TradingView
NewAmsterdam Pharma (NAMS) CAO exercises options and sells 40,000 shares - Stock Titan
Price to earnings forward of NewAmsterdam Pharma Company N.V. – LSX:A3DUAC - TradingView
NewAmsterdam Pharma Company NV (NAMS) Institutional Confidence - TradingKey
NewAmsterdam Pharma Company NV (NAMS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Breakeven On The Horizon For NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) - Moomoo
NewAmsterdam Pharma Company NV (NAMS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NewAmsterdam Pharma Company (NAMS) Proxy filing Summary - Quartr
NAMS News | NEWAMSTERDAM PHARMA CO NV (NASDAQ:NAMS) - ChartMill
NewAmsterdam Pharma Company NV (NAMSW) Institutional Confidence - TradingKey
NewAmsterdam Pharma Company NV (NAMSW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NewAmsterdam Pharma Company NV (NAMSW) Valuation: PE, PB & Fair Value Analysis - TradingKey
NewAmsterdam Pharma Company NV (NAMSW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
NewAmsterdam Pharma Company NV (NAMSW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
NewAmsterdam Pharma Company NV (NAMS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
NewAmsterdam Pharma Company NV (NAMS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NewAmsterdam Pharma Company NV (NAMS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
NewAmsterdam Pharma Company NV (NAMSW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
NewAmsterdam Pharma Company NV - TradingKey
NewAmsterdam Pharma Company NV (NAMSW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NewAmsterdam Pharma Company NV (NAMS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
The Technical Signals Behind (NAMS) That Institutions Follow - Stock Traders Daily
NewAmsterdam Pharma (NAMS) Slides 1.26% Amidst Cautious Trading, Support at $28.7 HoldsVol Target Rebalance - newsline.com
NAMSW SEC FilingsNewAmsterdam Pha 10-K, 10-Q, 8-K Forms - Stock Titan
NewAmsterdam Pharma Warrants (NAMSW) Plunge 11.78% as Sellers Dominate, Testing Key SupportVolume Weighted Price - newsline.com
NewAmsterdam Pharma Rises 3.17% as Shares Approach Resistance at $31.77Bollinger Band - newsline.com
A Look At NewAmsterdam Pharma (NAMS) Valuation After Recent Share Price Weakness - Yahoo Finance
(NAMSW) Risk Channels and Responsive Allocation - Stock Traders Daily
EBIT of NewAmsterdam Pharma Company N.V. – BX:NAMS - TradingView
NewAmsterdam Pharma Company (NAMS) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Billionaire Stanley Druckenmiller Likes This Small-Cap Pharma Stock in 2026 - Insider Monkey
All eyes on NewAmsterdam Pharma earnings as pipeline advances - Investing.com
Precision Trading with Newamsterdam Pharma Company N.v. (NAMS) Risk Zones - Stock Traders Daily
All eyes on NewAmsterdam Pharma earnings as pipeline advances By Investing.com - Investing.com Nigeria
Capital World Investors holds 10.4% of NewAmsterdam Pharma (NAMS) - Stock Titan
Newamsterdam Pharma Company Nv (NAMS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Newamsterdam Pharma Company Nv 주식 (NAMS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Kooij Louise Frederika | Chief Accounting Officer |
Jun 22 '26 |
Sale |
30.20 |
40,000 |
1,208,159 |
24,353 |
| Kooij Louise Frederika | Chief Accounting Officer |
May 26 '26 |
Option Exercise |
10.07 |
65,000 |
654,500 |
89,353 |
| Kooij Louise Frederika | Chief Accounting Officer |
May 26 '26 |
Sale |
35.69 |
65,000 |
2,319,850 |
24,353 |
0.82%
0.85%
자본화:
|
볼륨(24시간):